Evidence map›Paper›PMID 31532206›Full record

ArticleJournal of natural products2019

Development of High-Throughput Fluorescent-Based Screens to Accelerate Discovery of P2X Inhibitors from Animal Venoms.

Lucka Bibic, Volker Herzig, Glenn F King, Leanne Stokes

Open access · hybridAbstract read
In one paragraph

Article in Journal of natural products, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Centipede Venom: A Potential Source of Ion Channel Modulators.International journal of molecular sciences · 2022
    Review
  6. Recent Updates of Natural and Synthetic URAT1 Inhibitors and Novel Screening Methods.Evidence-based complementary and alternative medicine : eCAM · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Lucka BibicSchool of Pharmacy , University of East Anglia , Norwich Research Park, Norwich NR4 7TJ , U.K.ORCID 0000-0002-0355-0740
Volker HerzigInstitute for Molecular Bioscience , University of Queensland , St Lucia , QLD 4072 , Australia.
Glenn F KingInstitute for Molecular Bioscience , University of Queensland , St Lucia , QLD 4072 , Australia.ORCID 0000-0002-2308-2200
Leanne StokesSchool of Pharmacy , University of East Anglia , Norwich Research Park, Norwich NR4 7TJ , U.K.
The University of Queensland · AUUniversity of East Anglia · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Animal venoms can play an important role in drug discovery, as they are a rich source of evolutionarily tuned compounds that target a variety of ion channels and receptors. To date, there are six FDA-approved drugs derived from animal venoms, with recent work using high-throughput platforms providing a variety of new therapeutic candidates. However, high-throughput methods for screening animal venoms against purinoceptors, one of the oldest signaling receptor families, have not been reported. Here, we describe a variety of quantitative fluorescent-based high-throughput screening (HTS) cell-based assays for screening animal venoms against ligand-gated P2X receptors. A diverse selection of 180 venoms from arachnids, centipedes, hymenopterans, and cone snails were screened, analyzed, and validated, both analytically and pharmacologically. Using this approach, we performed screens against human P2X3, P2X4, and P2X7 using three different fluorescent-based dyes on stable cell lines and isolated the active venom components. Our HTS assays are performed in 96-well format and allow simultaneous screening of multiple venoms on multiple targets, improving testing characteristics while minimizing costs, specimen material, and testing time. Moreover, utilizing our assays and applying them to the other natural product libraries, rather than venoms, might yield other novel natural products that modulate P2X activity.

Indexed as

Drug DiscoveryAnimalsCell LineHigh-Throughput Screening AssaysHumansPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2XSpectrometry, FluorescenceVenomsPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2XVenoms

Identifiers

PMID31532206
PMCPMC7123434
OpenAlexW2973785834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.